Datroway® (datopotamab deruxtecan, Dato-DXd, DS-1062a) has also received regulatory approval from both the FDA and the EMA for the treatment of unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer in patients previously treated with endocrine therapy and chemotherapy [14,15]. This evidence concerns the gene NR4A1 and breast carcinoma.